WO2012060783A1 - THE USE OF β-D-GLUCAN TO REDUCE THE ADVERSE EFFECT OF THE IMMUNE RESPONSE DEPRESSION INDUCED BY EXCESSIVE PHYSICAL EXERCISE - Google Patents
THE USE OF β-D-GLUCAN TO REDUCE THE ADVERSE EFFECT OF THE IMMUNE RESPONSE DEPRESSION INDUCED BY EXCESSIVE PHYSICAL EXERCISE Download PDFInfo
- Publication number
- WO2012060783A1 WO2012060783A1 PCT/SK2011/050016 SK2011050016W WO2012060783A1 WO 2012060783 A1 WO2012060783 A1 WO 2012060783A1 SK 2011050016 W SK2011050016 W SK 2011050016W WO 2012060783 A1 WO2012060783 A1 WO 2012060783A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- glucan
- exercise
- physical exercise
- excessive physical
- immune response
- Prior art date
Links
- 230000000694 effects Effects 0.000 title claims abstract description 34
- FYGDTMLNYKFZSV-WFYNLLPOSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,3s,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-WFYNLLPOSA-N 0.000 title claims abstract description 28
- 229920002498 Beta-glucan Polymers 0.000 title claims abstract description 28
- 230000028993 immune response Effects 0.000 title claims abstract description 10
- 230000002411 adverse Effects 0.000 title abstract description 9
- 210000000822 natural killer cell Anatomy 0.000 claims abstract description 29
- 229920001503 Glucan Polymers 0.000 claims abstract description 10
- 230000002538 fungal effect Effects 0.000 claims abstract description 5
- 235000001603 Pleurotus ostreatus Nutrition 0.000 claims abstract description 4
- 240000001462 Pleurotus ostreatus Species 0.000 claims abstract description 4
- 238000011156 evaluation Methods 0.000 claims abstract description 3
- 239000002955 immunomodulating agent Substances 0.000 claims abstract description 3
- 229940121354 immunomodulator Drugs 0.000 claims abstract description 3
- 230000002584 immunomodulator Effects 0.000 claims abstract description 3
- 239000000902 placebo Substances 0.000 description 8
- 229940068196 placebo Drugs 0.000 description 8
- 210000000987 immune system Anatomy 0.000 description 6
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 239000012636 effector Substances 0.000 description 3
- 230000036737 immune function Effects 0.000 description 3
- 230000002101 lytic effect Effects 0.000 description 3
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000004820 blood count Methods 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 210000000207 lymphocyte subset Anatomy 0.000 description 2
- 230000037081 physical activity Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- AOFUBOWZWQFQJU-SNOJBQEQSA-N (2r,3s,4s,5r)-2,5-bis(hydroxymethyl)oxolane-2,3,4-triol;(2s,3r,4s,5s,6r)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O.OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O AOFUBOWZWQFQJU-SNOJBQEQSA-N 0.000 description 1
- 231100000023 Cell-mediated cytotoxicity Toxicity 0.000 description 1
- 206010057250 Cell-mediated cytotoxicity Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 1
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 1
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 1
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 1
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000005890 cell-mediated cytotoxicity Effects 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 235000020937 fasting conditions Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/20—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents
- A23L29/269—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of microbial origin, e.g. xanthan or dextran
- A23L29/271—Curdlan; beta-1-3 glucan; Polysaccharides produced by agrobacterium or alcaligenes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Definitions
- This invention concerns the use of ⁇ -D-Glucan to reduce the adverse effects that are associated with the immune response (immune system) depression induced by stressful and exhausting physical exercise, particularly in top athletes.
- the ⁇ -D-Glucans (functional polysaccharides) belong to a group of biological response modifiers and are involved in bolstering immune function (Sherwood, E.R., Williams, D.L., and DiLuzio, N.R. 1986, J. Biol. Response Mod. 5: 504-526; Browder, W., Williams, D., Pretus, H. 5 Olivero, G., Enrichens, F., Mao, P., et al. 1990, Ann. Surg. 211 : 605-613; Pretus, H.A., Ensley, H.E., McNamee, R.B., Jones, E.L., Browder, I.W., and Williams, D.L. 1991, J.
- the aim of this invention is to reduce the adverse effects associated with the immune system depression induced by stressful and exhausting physical exercise. Disclosure of Invention
- ⁇ -D-Glucan is used as an immunomodulator to reduce the adverse depression of the immune response following excessive physical exercise.
- ⁇ -D-Glucan is a fungal P(l,3/1,6)-D-Glucan prepared from the oyster mushroom.
- the evaluation the immune response was based on the assessment of NK cell activity immediately prior to excessive physical exercise, within 10 minutes following exercise, and following a relaxation period of 50 to 70 minutes post-exercise.
- NK cell activity after a 50- to 70-minute relaxation period following excessive physical exercise was significantly higher in subjects who had taken ⁇ -D-Glucan compared to those who were given a placebo. Furthermore, this activity was approximately equal to that measured prior excessive physical exercise among subjects who had taken ⁇ -D-Glucan; the mean decrease in NK cell activity (pre-exercise level vs. after the relaxation period) was 3.5% in subjects who had taken ⁇ -D-Glucan and 29% in subjects given the placebo.
- NK cell activity after a 50- to 70-minute relaxation period following excessive physical exercise was virtually unaltered in subjects administered ⁇ -D-Glucan.
- the ⁇ -D-Glucan used in the studies described below was in the form of the commercially prepared Imunoglukan, which is derived from the oyster mushroom.
- Exercise in the form of a gradual bicycle test until exhaustion, was performed by each subject, and the following parameters were measured: blood count and lymphocyte subpopulation analysis from relative and absolute counts (with an emphasis on NK cells, i.e., the NK cell subpopulations CD16 ⁇ , CD8 ⁇ , and CD56 ⁇ and NK cell activity), IgA, IgM, IgG, C3, and C4 levels and Cortisol levels. These parameters were measured prior to exercise, 5 minutes after exercise and after one hour of relaxation following exercise. The athletes were also divided into two therapeutic groups.
- glucan group ingested 100 mg of Imunoglukan and 100 mg of vitamin C in the morning under fasting conditions and prior to exercise
- placebo group ingested a placebo (100 mg of fructose and 100 mg of vitamin C). Both groups adhered to this treatment regimen over the course of 2 months, which was concurrent with their summer training preparation. Two athletes did not complete the study for personal reasons; one was a skier, one was a figure skater, and both were in the glucan group.
- Venous blood was sampled using the Vacutainer blood-draw system in the morning before physical exercise and was analysed with respect to the blood counts and leucocyte and lymphocyte subpopulations (4 ml, K 3 EDTA). Meanwhile, NK cell activity was assessed from heparinised blood samples (7 ml, Na 2 Heparin). The results of this assessment served as the baseline values. A second blood sampling was performed 5 minutes after exercise, and a third sampling was collected after one hour of relaxation following exercise. Both samples were subjected to the same analyses as the baseline sample.
- NK cell activity was conducted using a flow cytometer. Each NK cell activity value was stated in lytic units (LU), which indicated the number of effectors necessary to achieve 20% lysis of 10,000 target cells and was expressed per 10 7 effectors (LU 20 /IO 7 effectors). This NK cell activity value was the only parameter for which a statistically significant difference between the two therapeutic groups was observed (Fig. 1). A difference was also observed in the total NK cell number, but this disparity was not statistically significant.
- LU lytic units
- NK cell activity values expressed in lytic units (LU) for both the glucan and the placebo groups are plotted in Figure.
- NK cell activity decreased below the baseline value, by 28% on average, in the placebo group. Accordingly, the depression in the NK cell number during relaxation after previous physical stress was also accompanied by a functional decrease in NK cell activity. In contrast, we did not observe a decrease in NK cell activity below the baseline value after relaxation in the group that had received glucan.
- NK cell activity after the 50- to 70-minute relaxation period following excessive physical exercise increased by an average of 1.8% in subjects who were administered ⁇ -D-Glucan and decreased by an average of 28% in subjects who were given the placebo. Accordingly, NK cell activity in the group who had taken ⁇ -D-Glucan was virtually unaltered by excessive physical exercise.
- the subjects were assessed in a similar manner as previously described; however, they were administered 180 mg of ⁇ -D-Glucan instead of 100 mg.
- the NK cell activity value after the 50- to 70-minute relaxation period following physical exercise for subjects who received ⁇ -D-Glucan was virtually identical to that the NK cell activity that was measured prior to physical exercise.
- This invention can be used primarily in the field of sports medicine, used primarily by athletes, namely by top sportsmen.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nutrition Science (AREA)
- Epidemiology (AREA)
- Polymers & Plastics (AREA)
- Immunology (AREA)
- Food Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dispersion Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SKPP50049-2010 | 2010-11-06 | ||
SK50049-2010A SK500492010A3 (sk) | 2010-11-06 | 2010-11-06 | Use of beta-D-glucane for decreasing undesirable effect of depression of immune response to excessive physical strain |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2012060783A1 true WO2012060783A1 (en) | 2012-05-10 |
Family
ID=45554778
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/SK2011/050016 WO2012060783A1 (en) | 2010-11-06 | 2011-11-05 | THE USE OF β-D-GLUCAN TO REDUCE THE ADVERSE EFFECT OF THE IMMUNE RESPONSE DEPRESSION INDUCED BY EXCESSIVE PHYSICAL EXERCISE |
Country Status (2)
Country | Link |
---|---|
SK (1) | SK500492010A3 (sk) |
WO (1) | WO2012060783A1 (sk) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3858362A1 (en) * | 2020-01-29 | 2021-08-04 | Pleuran, s.r.o. | Beta-glucan for use in enhancement of anti-tumor immunity in remission |
WO2021152497A1 (en) * | 2020-01-29 | 2021-08-05 | Pleuran, S.R.O. | Beta-glucan for use in modulation of an immune response in a remission |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005067977A1 (en) * | 2004-01-14 | 2005-07-28 | Pleuran, S.R.O. | Method of preparation of a fungal glucane hydrogel having antibacterial and immunostimulant activity, and use thereof |
DE202004013521U1 (de) * | 2004-08-30 | 2006-01-05 | Almapharm Christian F.A. Botzenhardt Gmbh + Co | Präparat aus beta-Glucan und Nukleotid zur Verabreichung an Tiere |
WO2009042230A1 (en) * | 2007-09-27 | 2009-04-02 | Biopolymer Engineering, Inc. Dba Biothera, Inc | ß-GLUCAN TREATMENT OF UPPER RESPIRATORY TRACT INFECTION SYMPTOMS AND PSYCHOLOGICAL WELL-BEING |
-
2010
- 2010-11-06 SK SK50049-2010A patent/SK500492010A3/sk not_active Application Discontinuation
-
2011
- 2011-11-05 WO PCT/SK2011/050016 patent/WO2012060783A1/en active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005067977A1 (en) * | 2004-01-14 | 2005-07-28 | Pleuran, S.R.O. | Method of preparation of a fungal glucane hydrogel having antibacterial and immunostimulant activity, and use thereof |
DE202004013521U1 (de) * | 2004-08-30 | 2006-01-05 | Almapharm Christian F.A. Botzenhardt Gmbh + Co | Präparat aus beta-Glucan und Nukleotid zur Verabreichung an Tiere |
WO2009042230A1 (en) * | 2007-09-27 | 2009-04-02 | Biopolymer Engineering, Inc. Dba Biothera, Inc | ß-GLUCAN TREATMENT OF UPPER RESPIRATORY TRACT INFECTION SYMPTOMS AND PSYCHOLOGICAL WELL-BEING |
Non-Patent Citations (3)
Title |
---|
DAVIS ET AL: "Effects of oat beta-glucan on innate immunity and infection after exercise stress", MEDICINE AND SCIENCE IN SPORTS AND EXERCISE, LIPPINCOTT WILLIAMS & WILKINS, BALTIMORE, MD, US, vol. 36, no. 8, 1 January 2004 (2004-01-01), pages 1321 - 1327, XP008127608, ISSN: 0195-9131 * |
KATARINA BERGENDIOVA ET AL: "Pleuran (Î-glucan from) supplementation, cellular immune response and respiratory tract infections in athletes", EUROPEAN JOURNAL OF APPLIED PHYSIOLOGY, SPRINGER, BERLIN, DE, vol. 111, no. 9, 20 January 2011 (2011-01-20), pages 2033 - 2040, XP019938793, ISSN: 1439-6327, DOI: 10.1007/S00421-011-1837-Z * |
TALBOTT S AND TALBOTT J: "Effect of BETA 1,3/1,6 GLUCAN on upper respiratory tract infection symptoms and mood state in marathon athletes", J SPORTS SCI MED, vol. 8, 1 December 2009 (2009-12-01), pages 509 - 519, XP009158119 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3858362A1 (en) * | 2020-01-29 | 2021-08-04 | Pleuran, s.r.o. | Beta-glucan for use in enhancement of anti-tumor immunity in remission |
WO2021152497A1 (en) * | 2020-01-29 | 2021-08-05 | Pleuran, S.R.O. | Beta-glucan for use in modulation of an immune response in a remission |
Also Published As
Publication number | Publication date |
---|---|
SK500492010A3 (sk) | 2012-06-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Romeo et al. | Physical activity, immunity and infection | |
Maggini et al. | Feeding the immune system: the role of micronutrients in restoring resistance to infections. | |
Peake et al. | Recovery of the immune system after exercise | |
Simpson et al. | Exercise and the regulation of immune functions | |
Pae et al. | Nutritional modulation of age-related changes in the immune system and risk of infection | |
Gleeson et al. | Effects of a Lactobacillus salivarius probiotic intervention on infection, cold symptom duration and severity, and mucosal immunity in endurance athletes | |
Wintergerst et al. | Contribution of selected vitamins and trace elements to immune function | |
Zaldivar et al. | Constitutive pro-and anti-inflammatory cytokine and growth factor response to exercise in leukocytes | |
Street et al. | Glutamine supplementation in recovery from eccentric exercise attenuates strength loss and muscle soreness | |
Vassilakopoulos et al. | Antioxidants attenuate the plasma cytokine response to exercise in humans | |
Jung et al. | Effects of Panax ginseng supplementation on muscle damage and inflammation after uphill treadmill running in humans | |
Witard et al. | High dietary protein restores overreaching induced impairments in leukocyte trafficking and reduces the incidence of upper respiratory tract infection in elite cyclists | |
Shephard et al. | Acute and chronic over-exertion: do depressed immune responses provide useful markers? | |
Papacosta et al. | Effects of intensified training and taper on immune function | |
Suzuki et al. | Efficacy of oral administration of Lentinula eododes mycelia extract for breast cancer patients undergoing postoperative hormone therapy | |
Rossouw et al. | The effect of creatine monohydrate loading on maximal intermittent exercise and sport-specific strength in well trained power-lifters | |
Saygin et al. | Effect of chronic exercise on immunoglobin, complement and leukocyte types in volleyball players and athletes | |
Nakata et al. | Weight loss maintenance for 2 years after a 6-month randomised controlled trial comparing education-only and group-based support in Japanese adults | |
Baek et al. | Effects of lifelong spontaneous exercise on the M1/M2 macrophage polarization ratio and gene expression in adipose tissue of super-aged mice | |
Gleeson | Immune function and exercise | |
Franca et al. | Spirulina does not decrease muscle damage nor oxdidative stress in cycling athletes with adequate nutritional status. | |
Forbes et al. | Whey protein isolate supplementation while endurance training does not Alter cycling performance or immune responses at rest or after exercise | |
WO2012060783A1 (en) | THE USE OF β-D-GLUCAN TO REDUCE THE ADVERSE EFFECT OF THE IMMUNE RESPONSE DEPRESSION INDUCED BY EXCESSIVE PHYSICAL EXERCISE | |
Przewłócka et al. | Combined probiotics with vitamin D3 supplementation improved aerobic performance and gut microbiome composition in mixed martial arts athletes | |
Wang et al. | Echinacea purpurea extract affects the immune system, global metabolome, and gut microbiome in wistar rats |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11813836 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 05/08/2013). |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 11813836 Country of ref document: EP Kind code of ref document: A1 |